Q4 2022 Results
Company overview
Financial review
2023 priorities
Appendix
INNOVATION
Prioritizing pipeline to high-value innovative medicines
Refining our proven development engine with greater focus on asset value and improving R&D productivity
Proven development engine
Improving R&D productivity
Total NME approvals by company (1999-2021)1
42
34
==
1 Clear TA strategy with
disease area prioritization
30
NDA
12
BLA
28
20
23
23
18
14
Novartis Company A Company B Company C Company D Company E
2 Early assets with integrated
development plans, until
submission
3 Ongoing tracking and evaluation
of asset progression/value
4 End-to-end governance with
clear processes and ownership
Expected outcomes
Improved overall
success rate
(discovery to approval)
☐ Cycle time reduction
Increased asset value
✓ Industry leader across first-in-class approved NMEs²
1. US FDA NME approvals.
2. FDA: BCG analysis (2017-2021).
10 Investor Relations | Q4 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation